Free Newsletter
FEATURES >> The most interesting logos in Pharma
Endo plunks down $637M for Indevus
Endo Pharmaceuticals says it will be acquiring Indevus Pharmaceuticals for $370 million in cash and an additional $267 in future payouts, in an effort to move away from the pain-management business and into more-lucrative therapeutic areas with a less competition. Release
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
SHARE
WITH: